Salina Anderson
Psychiatric/Mental Health · Omaha, NENPI 1629461140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations.
Across 386 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$776
- AbbVie$630
- Alkermes, Inc.$502
- Supernus Pharmaceuticals, Inc.$426
- Johnson & Johnson$419
- Lundbeck LLC$329
- plus $3K from 21 others
What the payments were for
- Food & beverage$5,70498%
- Education$1062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- ARISTADA INITIO$125
How this compares
$5,810 in reported general payments places this provider in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 13 | $21,150 |
| RexultiBrexpiprazole | 14 | $20,154 |
| VraylarCariprazine Hcl | 12 | $17,454 |
| Jornay PmMethylphenidate Hcl | 28 | $11,728 |
| Ziprasidone Hcl | 47 | $2,088 |
| Paliperidone ErPaliperidone | 11 | $1,761 |
| Hydroxyzine Hcl | 19 | $829 |
| Fluvoxamine Maleate | 31 | $709 |
| Risperidone | 37 | $560 |
| Clonazepam | 37 | $486 |
| Venlafaxine Hcl | 12 | $466 |
| Mirtazapine | 23 | $442 |
| Divalproex Sodium | 30 | $403 |
| Doxepin Hcl | 12 | $276 |
| Trazodone Hcl | 16 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $776 | $21,15013 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $289 | $20,15414 claims |
| AbbVieVraylar | $630 | $17,45412 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $145 | $11,72828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Heather WilhelmOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.